The increased risk of amputation seen in the large, long-term Canagliflozin Cardiovascular Assessment Study (CANVAS) trial for canagliflozin, and select observational studies, merits further research but overall, there is currently no consistent evidence of SGLT2i exposure and increased risk of amputation
Semaglutide follows a very similar protocol to other GLP-1 drugs: First 2 Weeks: Early impacts, particularly appetite suppression, can occur
Brown RJ, Kelly MH, Collins MT
$210.00 Research Use Only Research Overview MOD-GRF (1-29) + Ipamorelin is a research peptide blend used to investigate growth hormone axis activation through complementary signaling pathways
It's a great community for staying on the cutting edge
Seek immediate medical attention if you experience: - Severe hypoglycemia symptoms (shakiness, confusion, sweating, rapid heartbeat) when combining GH peptides or GLP-1 medications with diabetes drugs